GlassScriptPhysician profile
Morey Filler
NPI 1437147063
$3,722.66
in general payments reported to CMS, 2019-2025
31 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $225 · 2021: $996 · 2022: $718 · 2023: $451 · 2024: $300 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.66 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $433.60 | 2021-2025 | |
| Coopersurgical, INC. | $365.72 | 2019-2025 | Paragard T 380a, Endosee, Paragard T 380a |
| Therapeuticsmd, INC. | $311.77 | 2019-2022 | |
| Hologic Sales and Service, LLC | $278.06 | 2019-2025 | Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $239.37 | 2019-2022 | |
| Amgen INC. | $193.94 | 2019-2024 | Prolia, Evenity |
| Astellas Pharma US INC | $184.29 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $155.60 | 2019-2022 | |
| Organon LLC | $136.63 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $106.21 | 2019-2020 | |
| Pfizer INC. | $74.54 | 2019-2023 | |
| Ascend Therapeutics US, LLC | $53.11 | 2021-2023 | |
| Evofem Biosciences, INC. | $46.37 | 2021-2022 | |
| Exeltis, USA INC. | $44.22 | 2019-2025 | Slynd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $43.43 | 2021 | |
| Shield Therapeutics INC | $31.04 | 2023 | Accrufer |
| Sage Therapeutics, LLC | $30.07 | 2022 | |
| Biogen, INC. | $28.46 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $27.25 | 2019 | |
| Avanos Medical | $25.08 | 2022 | |
| Sanofi Pasteur INC. | $23.91 | 2023 | |
| Olympus America INC. | $22.13 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.86 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.69 | 2022 | |
| Agile Therapeutics, INC. | $19.49 | 2021 | |
| Roche Diagnostics Corporation | $18.91 | 2019 | |
| Ethicon US, LLC | $17.99 | 2022 | |
| Aspira Women'S Health INC | $16.87 | 2019 | |
| Dysis Medical, INC. | $14.76 | 2022 | |
| Channel Medsystems, INC. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morey Filler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.